We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.48%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$621M
AUM Growth
+$72.3M
Cap. Flow
-$24.9M
Cap. Flow %
-4%
Top 10 Hldgs %
33.04%
Holding
112
New
30
Increased
19
Reduced
32
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.5M
2
NVMI
Nova
NVMI
+$15.3M
3
GLBE icon
Global E Online
GLBE
+$9.72M
4
TBLA icon
Taboola.com
TBLA
+$6.52M
5
META icon
Meta Platforms (Facebook)
META
+$6.21M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.82M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.35M
3
AMZN icon
Amazon
AMZN
+$5.55M
4
IRON icon
Disc Medicine
IRON
+$5.23M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$4.67M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Technology 15.8%
3 Communication Services 3.76%
4 Consumer Discretionary 3.08%
5 Utilities 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$44.6M 7.19%
+500,000
New +$37.1M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$40.8B
$25.8M 4.15%
2,469,100
+1,869,100
+312% +$17.5M
SNY icon
3
Sanofi
SNY
$103B
$24.8M 4%
499,515
– –
CYTK icon
4
Cytokinetics
CYTK
$10.5B
$18.7M 3.01%
223,820
-10,113
-4% -$366K
NVMI
5
Nova
NVMI
$12.4B
$18.1M 2.92%
+132,000
New +$15.3M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.69B
$16.7M 2.69%
772,964
-97
-0% -$1.49K
TSEM icon
7
Tower Semiconductor
TSEM
$24.8B
$16.1M 2.6%
528,300
+58,726
+13% +$1.53M
NICE icon
8
Nice
NICE
$5.79B
$13.5M 2.17%
67,718
+30,236
+81% +$5.44M
MRK icon
9
Merck
MRK
$322B
$13.5M 2.17%
123,600
– –
TEVA icon
10
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$13.4M 2.16%
1,284,000
-3,729,800
-74% -$34.8M
CLDX icon
11
Celldex Therapeutics
CLDX
$2.99B
$12.5M 2.01%
315,644
+135,644
+75% +$3.99M
JNJ icon
12
Johnson & Johnson
JNJ
$618B
$12.5M 2.01%
79,831
-15,000
-16% -$2.3M
META icon
13
Meta Platforms (Facebook)
META
$1.42T
$12.1M 1.95%
34,303
+19,083
+125% +$6.21M
AZN icon
14
AstraZeneca
AZN
$263B
$12.1M 1.95%
90,030
-52,500
-37% -$6.82M
BIIB icon
15
Biogen
BIIB
$30B
$12M 1.93%
46,346
+20,500
+79% +$5.04M
BBIO icon
16
BridgeBio Pharma
BBIO
$15.7B
$11.4M 1.83%
282,146
-63,391
-18% -$1.9M
GLBE icon
17
Global E Online
GLBE
$6.6B
$10.7M 1.72%
+269,794
New +$9.72M
FUSN
18
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$10.4M 1.68%
1,085,639
-268,619
-20% -$1.31M
KURA icon
19
Kura Oncology
KURA
$800M
$10.1M 1.63%
703,287
– –
NVO
20
Novo Nordisk
NVO
$208B
$9.63M 1.55%
93,080
– –
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.45B
$9.61M 1.55%
201,044
-58,091
-22% -$2.25M
MSFT icon
22
Microsoft
MSFT
$3.45T
$8.97M 1.44%
23,848
-10,594
-31% -$3.77M
ATXS
23
DELISTED
Astria Therapeutics
ATXS
$8.84M 1.42%
1,151,145
+570,546
+98% +$3.15M
INBX
24
DELISTED
Inhibrx, Inc. Common Stock
INBX
$8.61M 1.39%
226,551
-29,820
-12% -$639K
AMZN icon
25
Amazon
AMZN
$2.92T
$8.46M 1.36%
55,676
-39,624
-42% -$5.55M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sphera Funds Management held 112 positions worth $621M, up 13% from $549M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $24.9M in Q4 2023, closing 13 positions and reducing 32 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $6.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 61% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in Nova worth $18.1M.

  • Sphera Funds Management's largest Q4 2023 buy was Nova: 132,000 shares worth $18.1M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q4 2023, an estimated $17.5M increase.
  • Sphera Funds Management's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $6.82M.
  • Sphera Funds Management fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.35M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $621M portfolio in Q4 2023.
  • Sphera Funds Management opened 30 new positions and closed 13 in Q4 2023.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $621M.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.